GALECTIN THERAPEUTICS INC - 8-K Filing
Galectin Therapeutics reports Q3 2026 net loss of $3.6 million and announces debt-to-equity conversion of $105.8 million. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $GALT